12/1
01:23 pm
crdl
Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.